University of Florence, Italy.
Medical Physics Unit, Azienda USL Toscana Centro, Florence, Italy.
Phys Med. 2018 May;49:129-134. doi: 10.1016/j.ejmp.2017.11.012. Epub 2017 Dec 6.
Aim of this work was to study how the detector resolution can affect the clinical significance of SBRT pre-treatment volumetric modulated arc therapy (VMAT) verification results.
Three detectors (PTW OCTAVIUS 4D 729, 1500 and 100 SRS) used in five configurations with different resolution were compared: 729, 729 merged, 1500, 1500 merged and 1000 SRS. Absolute local gamma passing rates of 3D pre-treatment quality assurance (QA) were evaluated for 150 dose distributions in 30 plans. Five different kinds of error were introduced in order to establish the detection sensitivity of the three devices. Percentage dosimetric differences were evaluated between planned dosevolume histogram (DVH) and patients' predicted DVH calculated by PTW DVH 4D® software.
The mean gamma passing rates and the standard deviations were 92.4% ± 3.7%, 94.6% ± 1.8%, 95.3% ± 4.2%, 97.4% ± 2.5% and 97.6% ± 1.4 respectively for 729, 729 merged, 1500, 1500 merged and 1000 SRS with 2% local dose/2mm criterion. The same trend was found on the sensitivity analysis: using a tight gamma analysis criterion (2%L/1mm) only the 1000 SRS detected every kind of error, while 729 and 1500 merged detected three and four kinds of error respectively. Regarding dose metrics extracted from DVH curves, D50% was within the tolerance level in more than 90% of cases only for the 1000 SRS.
The detector resolution can significantly affect the clinical significance of SBRT pre-treatment verification results. The choice of a detector with resolution suitable to the investigated field size is of main importance to avoid getting false positive.
本研究旨在探讨探测器分辨率如何影响立体定向体部放射治疗(SBRT)容积旋转调强放疗(VMAT)预处理验证结果的临床意义。
比较了三种探测器(PTW OCTAVIUS 4D 729、1500 和 100 SRS)在五种不同分辨率配置下的表现:729、729 合并、1500、1500 合并和 1000 SRS。对 30 个计划中的 150 个剂量分布进行了 3D 预处理质量保证(QA)的绝对局部伽马通过率评估。为了确定三种设备的检测灵敏度,引入了五种不同类型的误差。评估了计划剂量体积直方图(DVH)与 PTW DVH 4D®软件计算的患者预测 DVH 之间的剂量差异百分比。
对于 729、729 合并、1500、1500 合并和 1000 SRS,2%局部剂量/2mm 标准下,平均伽马通过率和标准差分别为 92.4%±3.7%、94.6%±1.8%、95.3%±4.2%、97.4%±2.5%和 97.6%±1.4%。在灵敏度分析中也发现了相同的趋势:使用严格的伽马分析标准(2%L/1mm),只有 1000 SRS 检测到了所有类型的误差,而 729 和 1500 合并分别检测到了三种和四种误差。对于从 DVH 曲线提取的剂量指标,只有 1000 SRS 有超过 90%的 D50%在容差范围内。
探测器分辨率会显著影响 SBRT 预处理验证结果的临床意义。选择适合所研究射野大小的分辨率的探测器对于避免假阳性至关重要。